News Releases Sumitomo Pharmaceuticals 2005 Jul. 6, 2005 Sumitomo Pharmaceuticals Signs Agreement with Merck & Co., Inc. Forming Global Partnership for SM13496 (lurasidone), an Atypical Antipsychotic Compound Jun. 30, 2005 Sumitomo Licenses an Antitumor Drug, Amrubicin Hydrochloride, to Conforma May 18, 2005 Sumitomo Licenses Breakthrough Antibiotic SMP-601 to Prote Apr. 28, 2005(PDF/30KB) Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement 2005 2004 2003 2002 2001 2000